Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
FAIL · Does not pass the screen
347.00 USD
At the last full screen 2026-09-11
Screened 2026-09-11 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Krystal Biotech, Inc. holds its Accumulation at $347.00. Consolidating, no directional conviction, held for 205 days.
As held on the ledger · 2026-09-11
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 205 days
Price at the screen
$347.00
Valuation
43.48 trailing · 36.92 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.54
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.70%
Below 33%
Interest-bearing debt is just 0.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
9.60%
Below 33%
Cash held in interest-bearing accounts and securities is 9.6% of assets, under the one-third limit.
Pass
Receivables
46.76%
Below 49%
Money owed to the company is 46.8% of assets, under the 49% limit.
Pass
Revenue purity
7.24%
Below 5%
7.2% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. The price runs 14.2% above the base estimate.
Third-party analyst targets: 8 covering, consensus None. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
One approved gene fix, yet priced for perfection
Krystal Biotech sells a single gene therapy that treats a rare and painful skin disorder with one dose. The product already drives 32 percent revenue growth and a 54 percent profit margin, yet the shares sit 16 percent above our fair value at a 35 times forward earnings multiple.
We pass because the current price leaves no margin of safety. Strong analyst targets and clean ethical marks cannot offset the fact that investors are paying a premium for a company with just one commercial asset and an unknown competitive moat.
The main risk is simple: any delay in new pipeline launches or pressure on pricing would hit earnings hard at this valuation. Peak earnings and a high multiple together often signal a trap rather than an opportunity. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KRYS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter.
2026-08-04Markup$366.85+15.4%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323.
2026-07-18Markup$317.97+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323.
2026-07-03Markup$317.97+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$317.97Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
